News >

Experts Discuss Frontline CDK4/6 Inhibitors in ER+ Breast Cancer

Angelica Welch
Published: Saturday, May 19, 2018

Dennis J. Slamon, MD, PhDDennis J. Slamon, MD, PhD

The discovery of the estrogen receptor in the mid-twentieth century by Elwood V. Jensen, PhD, marked a new era of treatment for patients with hormone receptor (HR)-positive breast cancer. As researchers continue to learn how to best target the estrogen receptor, new treatments are emerging in this landscape. 

Clinical studies of the hormonal therapy fulvestrant (Faslodex) offered the first glimmer of hope that something other than chemotherapy could induce durable, lasting responses in these patients, said Hurvitz. Since then, fulvestrant has become a staple in the treatment of postmenopausal patients with HR-positive breast cancer. 

The Introduction of CDK4/6 Inhibitors

For HR-positive patients with estrogen receptor (ER)-positive breast cancer, CDK4/6 inhibitors have emerged as a very potent therapy. Slamon, the director of Clinical/Translational Research, Revlon/UCLA Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, said that this was based on a breakthrough therapy that almost did not happen. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication